Human papillomavirus (HPV) is the most common sexually transmitted infection, with a lifetime risk of infection of approximately 80% \[[@CIT0001]\]. HPV infections are the cause of genital warts and cervical cancer and are strongly associated with anal, penile, oropharyngeal, vaginal, and vulvar cancers \[[@CIT0002]\]. Currently, 3 prophylactic HPV vaccines are available: bivalent, quadrivalent, and nonvalent. All 3 vaccines were originally approved in 3-dose (3D) schedules (0, 1 or 2, and 6 months). Given the lack of a correlate of protection and the long time between onset of an HPV infection and most of its sequelae, the International Agency for Research on Cancer has endorsed several intermediate endpoints for the evaluation of HPV vaccines. To assess the effect of the HPV vaccine in women aged 16--26 years, originally cervical intraepithelial neoplasia grade 2 (CIN2+) or higher was used as an outcome. Now, persistent infections for 6 months or longer are also considered as an outcome for individuals aged ≥16 years. For evaluation in individuals aged \<16 years, an immunobridging principle is used. Immunobridging assumes that if the immunogenicity can be shown to be comparable between groups, the efficacy will be comparable also \[[@CIT0003]\]. For the HPV vaccine, this means that if antibody responses in young adolescents aged 9--15 years are comparable to the antibody responses in young adults aged ≥16 years, among whom clinical efficacy against CIN2+ has been shown, effectiveness is assumed to be comparable \[[@CIT0004], [@CIT0005]\]. Hence, based on immunobridging studies, 2 doses of vaccine have been recommended for girls aged \<15 years \[[@CIT0006], [@CIT0007]\].

Recommendation for the 2-dose (2D) schedule was based on noninferior immunogenicity among girls compared with 3 doses for women up to 26 years, as described above \[[@CIT0007]\]. Subsequently, many countries have implemented the 2-dose schedule in their immunization programs \[[@CIT0010]\]. However, continued monitoring of the duration of antibody persistence has been advised \[[@CIT0011], [@CIT0012]\]. Follow-up of the 2D schedule for 60 months after vaccination has been reported. It was found that there was no significant difference in the decline in antibody titers from 36 to 60 months in girls who received 2 or 3 doses, indicating a comparable decay in antibody levels \[[@CIT0011]\]. However, longer-term antibody duration has not been reported for 2 doses. Here, we report the antibody responses up to 120 months after vaccination with 2D or 3D of the quadrivalent HPV (4vHPV) vaccine.

METHODS {#s1}
=======

Study Participants {#s2}
------------------

This was a post hoc analysis of a phase 3, postlicensure, age-stratified, noninferiority immunogenicity trial. The study included 3 groups that received the 4vHPV vaccine: girls aged 9--13 years who were randomized to receive either 2 doses or 3 doses (2D and 3D girls) and women aged 16--26 years who received 3 doses (3D women) \[[@CIT0007], [@CIT0011]\]. At 60 months postvaccination, only the 2D and 3D girls were compared. Participants were eligible for this 120-month follow-up study if they agreed to be contacted for future studies at the start of the original trial and if they also contributed to the 60-month evaluation for 2D and 3D girls \[[@CIT0011]\]. At 120 months postvaccination, eligible participants received an invitation letter and a follow-up phone call. Consenting participants provided a blood sample for serology. For the analyses reported here, data from participants were only included if they contributed to the study visits (day 1, months 7, 24, and 120) where data from all participants were collected. The relevant ethics boards of British Columbia, Nova Scotia, and Quebec approved the follow-up study.

Laboratory Analysis {#s3}
-------------------

Blinded antibody data for all time points were provided by Merck & Co, Inc, Kenilworth, New Jersey, at no cost for the study. Antibodies against HPV6, 11, 16, and 18 for all participants were measured using both the competitive Luminex immunoassay (cLIA) and total immunoglobulin G (IgG) assay (TIgG) \[[@CIT0013]\]. Seropositivity rates and geometric mean titers (GMTs) were calculated among participants at 120 months; seropositivity rates and GMTs for earlier time points postvaccination have been previously reported \[[@CIT0007], [@CIT0011]\]. Seropositivity cutoffs for the cLIA were 20 mMU/mL, 16 mMU/mL, 20 mMU/mL, and 24 mMU/mL for HPV6, 11, 16, and 18, respectively \[[@CIT0014]\]. Seropositivity cutoffs for the TIgG were 15 mMU/mL, 15 mMU/mL, 7 mMU/mL, and 10 mMU/mL for HPV6, 11, 16, and 18, respectively \[[@CIT0015]\].

Statistical Analyses {#s4}
--------------------

Seropositivity rates and GMTs were compared between the different study groups for each HPV vaccine type at day 1 and months 7, 24, and 120 postvaccination. For GMT ratios, noninferiority was defined as the lower bound of the 2-sided 95% confidence interval (CI) around the GMT ratio being greater than 0.5, when comparing the GMTs for 2D and 3D girls with those in women. \[[@CIT0016]\]. The paired sample *t* test and the 2-sample *t* test with unequal variances were used to explore the difference over time and to compute the *P* values based on the log scale of GMT values. Linear mixed-effects models on the assay natural log-transformed values were used to explore a possible difference in antibody decay over time between the groups. Statistical analyses were performed using SAS version 9.4 (SAS Institute Inc).

RESULTS {#s5}
=======

The flow of original study participants and of those included in the follow-up is shown in [Figure 1](#F1){ref-type="fig"}. A total of 210 participants were approached for the 120-month follow-up visit, and 114 (54.2%) agreed to participate (2D girls, n = 38; 3D girls, n = 39; 3D women, n = 37). After exclusion of those who did not participate at all study visits (ie, day 1 and months 7, 24, and 120 postvaccination), the analyses included 103 participants (2D girls, n = 35; 3D girls, n = 38; 3D women, n = 30). Compared with the 716 participants in the original study \[[@CIT0007]\] who did not participate at 120 months, 3D girls in this follow-up study were slightly younger (mean age 11.3 years vs 11.9 years at the first visit; *P* = .04); 3D women were less likely to be sexually active at recruitment (48.7% vs 68.1%; *P* = .03). For girls receiving 2 doses, there was no significant difference between the original trial cohort and those participating in this follow-up study ([Table 1](#T1){ref-type="table"}). At both the first study visit and at 120 months postvaccination, we did not observe a difference in 2D and 3D girls with regard to sociodemographics or sexual behavior ([Supplementary Table A](#sup1){ref-type="supplementary-material"}).

###### 

Comparison of Characteristics at First Study Visit/Vaccination Initiation of Participants Included in the Follow-up Study vs Participants Not Included in Follow-up

                                            Girls         Women                                                                                 
  ----------------------------------------- ------------- ------------- ----- ------------- ------------- ----- --------------- --------------- -----
  Age, mean (SD), y                         11.8 (1.3)    11.9 (1.2)    .68   11.9 (1.3)    11.3 (1.6)    .04   18.9 (2.7)      18.2 (2.5)      .21
  Body mass index (kg/m^2^), mean (SD)      19.6 (3.5)    19.5 (3.3)    .90   19.9 (4.0)    18.9 (2.7)    .18   23.0 (4.0)      22.3 (2.3)      .51
  Weight (kg), mean (SD)                    46.9 (10.7)   47.0 (11.5)   .94   48.4 (12.4)   44.2 (11.2)   .08   62.2 (12.4)     62.7 (8.7)      .42
  Postmenarchal, n (%)                      98 (44.1)     19 (50)       .60   104 (47.1)    13 (33.3)     .12   273 (100.0)     37 (100.0)      ...
  Sexually active, n (%)                    0 (0.0)       0 (0.0)             0 (0.0)       0 (0.0)             186 (68.1)      18 (48.7)       .03
  Age at sexual debut, mean (range), y      ...           ...           ...   ...           ...           ...   16.7 (13--24)   16.6 (14--19)   .96
  Number of sexual partners, mean (range)   ...           ...           ...   ...           ...           ...   2.1 (1--4)      1.7 (1--4)      .97

Abbreviation: 2D, 2 doses; 3D, 3 doses; SD, standard deviation.

![Flow of participants throughout the study. Girls were aged 9--13 years at enrollment. Women were aged 16--26 years at enrollment. Abbreviation: HPV, human papillomavirus.](ciz887f0001){#F1}

At 120 months postvaccination, cLIA seropositivity rates were above 95% for all HPV vaccine types and all schedules, except HPV18, which had the lowest seropositivity observed among 3D women (60.0%; 95% CI, 40.6%--77.3%; [Figure 2](#F2){ref-type="fig"}). At 120 months, 2D and 3D girls had noninferior GMTs for all HPV vaccine types compared with 3D women. GMTs for 2D girls were noninferior at 120 months postvaccination compared with 3D girls for HPV6, 11, and 16 but not for HPV18 ([Table 2](#T2){ref-type="table"}). Trends in GMTs and seropositivity were comparable for the TIgG and the cLIA ([Supplementary Table B](#sup1){ref-type="supplementary-material"} and [Supplementary Figure 1](#sup1){ref-type="supplementary-material"}).

###### 

Summary of Competitive Luminex Immunoassay Geometric Mean Titers and Ratios at Day 1, Month 7, Month 24, and Month 120

              Girls   Women               GMT Ratio                                                                                          
  ----------- ------- ------------------- ----------- --------------------- ---- ------------------- ------------------- ------------------- -------------------
  Day 1                                                                                                                                      
  HPV6        35      4 (3--5)            38          4 (4--4)              30   4^a^                ...                 ...                 ...
  HPV11       35      4^a^                38          4^a^                  30   4 (4--5)            ...                 ...                 ...
  HPV16       35      6^a^                38          6 (5--6)              30   6^a^                ...                 ...                 ...
  HPV18       35      5^a^                38          5^a^                  30   5^a^                ...                 ...                 ...
  Month 7                                                                                                                                    
  HPV6        35      1941 (1059--3559)   38          2229 (1542--3219)     30   1081 (631--1852)    1.80 (0.80--4.03)   0.87 (0.44--1.73)   2.06 (1.11--3.83)
  HPV11       35      2325 (1711--3160)   38          2256 (1655--3075)     30   1705 (1134-2563)    1.36 (0.83--2.23)   1.03 (0.67--1.58)   1.32 (0.81--2.17)
  HPV16       35      5804 (3397--9918)   38          7721 (5237--11 384)   30   3889 (2246--6736)   1.49 (0.70--3.18)   0.75 (0.40--1.43)   1.99 (1.04--3.77)
  HPV18       35      1496 (1041--2147)   38          1995 (1318--3020)     30   718 (461--1117)     2.08 (1.20--3.63)   0.75 (0.43--1.29)   2.78 (1.53--5.06)
  Month 24                                                                                                                                   
  HPV6        35      298 (202--439)      38          313 (237--412)        30   205 (153--274)      1.46 (0.89--2.38)   0.95 (0.60--1.51)   1.53 (1.03--2.27)
  HPV11       35      376 (277--510)      38          395 (294--530)        30   310 (205--467)      1.21 (0.74--1.99)   0.95 (0.63--1.44)   1.28 (0.79--2.07)
  HPV16       35      1561 (1118--2179)   38          1472 (1063--2038)     30   978 (675--1418)     1.60 (0.98--2.60)   1.06 (0.67--1.68)   1.50 (0.93--2.44)
  HPV18       35      188 (125-282)       38          315 (202--489)        30   90 (54--150)        2.08 (1.11--3.90)   0.60 (0.33--1.08)   3.48 (1.80--6.71)
  Month 120                                                                                                                                  
  HPV6        35      154 (109--217)      38          164 (126--213)        30   111 (80--155)       1.39 (0.86--2.23)   0.94 (0.62--1.43)   1.48 (0.98--2.22)
  HPV11       35      133 (91--193)       38          148 (109--202)        30   134 (89--201)       .99 (0.58--1.71)    0.90 (0.56--1.44)   1.10 (0.68--1.82)
  HPV16       35      692 (492--973)      38          571 (416--784)        30   430 (264--699)      1.61 (0.91--2.85)   1.21 (0.77--1.92)   1.33 (0.77--2.30)
  HPV18       35      74 (47--118)        38          103 (67--160)         30   37 (21--65)         2.02 (0.99--4.10)   0.72 (0.38--1.34)   2.82 (1.42--5.58)

Abbreviations: 2D, 2 doses; 3D, 3 doses; CI, confidence interval; GMT, geometric mean titer; HPV, human papillomavirus.

^a^All responses for this HPV type in this group were below the detection limit.

![Seropositivity rates as measured by competitive Luminex immunoassay at different time points. Seropositivity rates of human papillomavirus 6/11/16/18 among 2-(2D) and 3-dose (3D) girls and 3D women up to 120 months postvaccination. Abbreviation: HPV, human papillomavirus.](ciz887f0002){#F2}

Between 24 and 120 months, there was a statistically significant reduction in GMTs for all HPV types for all groups (all *P* values \< .001; [Figure 3](#F3){ref-type="fig"}). We did not observe a significant difference in the development of GMT over time between the different study groups. The greatest rate of decline was found for HPV18 in 3D girls, log difference 1.11 (95% CI, 0.94--1.29), and the smallest decline was found among 3D women for HPV6, log difference 0.61 (95% CI, 0.32--0.91; [Table 3](#T3){ref-type="table"}). Trends were comparable for the TIgG and the cLIA (data not shown).

###### 

Difference in Competitive Luminex Immunoassay Geometric Mean Titers Between 24 and 120 Months Postvaccination as Estimated by a Linear Mixed Model

          Girls               Women                                                                          
  ------- ------------------- -------- ------------------- -------- ------------------- -------- ----- ----- -----
  HPV6    0.66 (0.39--0.93)   \<.001   0.65 (0.51--0.78)   \<.001   0.61 (0.32--0.91)   .002     .90   .94   .92
  HPV11   1.04 (0.89--1.19)   \<.001   0.98 (0.81--1.15)   \<.001   0.84 (0.48--1.20)   \<.001   .20   .36   .59
  HPV16   0.81 (0.61--1.02)   \<.001   0.95 (0.79--1.11)   \<.001   0.82 (0.43--1.22)   .002     .98   .50   .30
  HPV18   0.93 (0.65--1.21)   \<.001   1.11 (0.94--1.29)   \<.001   0.90 (0.45--1.35)   .003     .96   .44   .26

Abbreviations: 2D, 2 doses; 3D, 3 doses; CI, confidence interval; HPV, human papillomavirus.

![Kinetics of competitive Luminex immunoassay antibody titers over time. Geometric mean titers for 2- and 3-dose girls and 3-dose women up to 120 months postvaccination. Abbreviations: cLIA, competitive Luminex immunoassay; GMT, geometric mean titer; HPV, human papillomavirus.](ciz887f0003){#F3}

Although we observed declining antibody levels for all HPV types and all schedules, we did not observe a difference in the decay of antibody levels over time for the different schedules, since all interaction terms between time since first dose and schedule were nonsignificant ([Supplementary Table C](#sup1){ref-type="supplementary-material"}). Trends were comparable for the TIgG and the cLIA (data not shown).

DISCUSSION {#s6}
==========

At 120 months after their first dose of the HPV vaccine, 2D girls showed noninferior GMTs compared with 3D women, in whom efficacy had been established for all HPV vaccine types. Also, GMTs in 2D girls were noninferior to those in 3D girls, except for HPV18 when measured with cLIA. Measured with cLIA, seropositivity for all types was above 95% in all groups, except for HPV18. We did not observe a significant difference in the decline of antibody titers over time between 2D and 3D girls or between either 2D or 3D girls and 3D women. These data provide further reassurance in support of the World Health Organization recommendation for 2D schedules \[[@CIT0006]\].

Seropositivity rates for HPV18 decreased over time and were significantly lower for 3D women compared with 2D or 3D girls when measured with the cLIA. The cLIA is known to be less sensitive for HPV18 than other assays such as the pseudovirus neutralizing antibody assay or the TIgG immunoassay \[[@CIT0019]\]. Because of the great efficacy of the HPV vaccines, it has been impossible to distinguish a correlate of protection to date. Neutralizing antibodies are thought to be the principal mechanism of protection \[[@CIT0020]\]. However, factors other than antibody levels might influence protection \[[@CIT0021]\], especially in the longer term. Given the lack of a correlate of protection, the clinical value of our lower seropositivity rates cannot be defined within our study. While the lower seropositivity rates over time for HPV18 are in line with previous findings, this seemingly weaker antibody response has not been reflected in inferior protection against HPV-associated diseases \[[@CIT0022], [@CIT0023]\]. Joura et al showed declining seropositivity of up to 60% 44 months after vaccination in women, but efficacy at that time was still 98.4% (95% CI, 90.5%--100.0%) against HPV18-related cervical intraepithelial neoplasia/adenocarcinoma in situ of any grade \[[@CIT0023]\]. In our study, when measured with the TIgG, the seropositivity in 3D women (87.0%; 95% CI, 78.8%--95.1%) was still lower compared with girls (2D: 94.7%; 95% CI, 87.5%--100.0% and 3D: 92.3%; 95% CI, 83.7%--100.0%), but this was no longer significantly different.

We showed that GMTs for both 2D and 3D girls were statistically noninferior to those for 3D women up to 120 months after initiation of 4vHPV vaccination. The original approval of HPV vaccines for girls was based on noninferior immune responses compared with women, with the assumption that immunogenicity efficacy would also be comparable \[[@CIT0003]\]. Our findings confirm the durability of the immune response after 2D of 4vHPV vaccine for at least 10 years. Recently, effectiveness of 3D of the 4vHPV vaccine against CIN2+ vulvar and vaginal cancer to at least 10 years with indications for up to 12 years was shown in the Nordic countries among women who participated in the FUTURE II study and were vaccinated between age 15 and 26 years \[[@CIT0024]\]. Combining these recent results with the noninferior immunogenicity observed in our study, we can assume that girls vaccinated with the 4vHPV vaccine will be well protected for more than a decade.

We observed noninferior antibody titers for all HPV vaccine types in 2D girls compared with 3D girls up to 120 months when measured with the TIgG and for all types, except HPV18, when measured with the cLIA. It is not known how the lower antibody titers for HPV18 after 2D would impact effectiveness, given the current absence of a correlate of antibody levels required for protection from HPV infection. A recent study from India also showed noninferior antibody responses comparing 2D and 3D recipients within their own age group (15--18 years) up to 36 months \[[@CIT0025]\]. Also, continued responses were measured in this study up to 48 months postvaccination. In addition, in both arms of that study, no persistent infections with any of the vaccine types were found up to 7 years postvaccination, indicating comparable effectiveness \[[@CIT0026]\].

An important limitation of our study was the small size of the study groups compared with the number of women in the original trial. However, the study had sufficient statistical power to demonstrate noninferiority at 120 months. In addition, comparing those participants who did or did not participate in the follow-up, we did not find remarkable differences in participant characteristics among the girls and expect limited impact of these small differences on the persistence of antibodies. The 3D women in the follow-up study were less likely to be sexually active (48.7% vs 68.1%) at the start of the study compared with the women who were included in the original trial but did not participate at 120 months. This could have influenced the antibody titers because the 3D women included in this follow-up study were less likely to be previously exposed. Because the antibody titers for the different time points were tested at different times, we cannot exclude the possibility of slight variability in the observed antibody titers. However, the observed kinetics of antibody titers indicate no important or unexpected variability.

In conclusion, this is the first study to show the continued antibody responses of 2D compared with 3D of HPV vaccine with follow-up to 10 years. The 2D schedule of the 4vHPV vaccine is highly immunogenic, and antibody responses persisted up to 10 years postvaccination.

Supplementary Data {#s7}
==================

Supplementary materials are available at *Clinical Infectious Diseases* online. Consisting of data provided by the authors to benefit the reader, the posted materials are not copyedited and are the sole responsibility of the authors, so questions or comments should be addressed to the corresponding author.

###### 

Click here for additional data file.
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